Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Cash Flow (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Net Cash Flow for 12 consecutive years, with $65.4 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 377.26% to $65.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139.1 million through Dec 2025, up 584.95% year-over-year, with the annual reading at $139.1 million for FY2025, 584.95% up from the prior year.
  • Net Cash Flow hit $65.4 million in Q4 2025 for Viking Therapeutics, down from $66.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $140.1 million in Q1 2024 to a low of -$151.7 million in Q2 2024.
  • Historically, Net Cash Flow has averaged $6.9 million across 5 years, with a median of $5.2 million in 2022.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 1195.85% in 2023 and later plummeted 396.46% in 2024.
  • Year by year, Net Cash Flow stood at $15.1 million in 2021, then plummeted by 53.11% to $7.1 million in 2022, then surged by 158.1% to $18.3 million in 2023, then tumbled by 229.08% to -$23.6 million in 2024, then soared by 377.26% to $65.4 million in 2025.
  • Business Quant data shows Net Cash Flow for VKTX at $65.4 million in Q4 2025, $66.5 million in Q3 2025, and -$4.0 million in Q2 2025.